Journal: Drug Design, Development and Therapy
Article Title: Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities
Figure Lengend Snippet: Biochemical properties of HCA. ( A ) Activity–pH relationship curve; ( B ) activity–temperature relationship curve; ( C ) effects of Ca 2+ on the fibrinogen clotting activity; ( D ) effect of PMSF on the clotting time of fibrinogen solution after the addition of HCA. The values shown are the mean values ± SEM (n=3). Abbreviations: HCA, hemocoagulase agkistrodon; PMSF, phenylmethanesulfonyl fluoride; SEM, standard error of mean.
Article Snippet: HCA (Beijing, Konruns Pharmaceutical Co., Ltd.); DEAE-Sepharose Fast Flow and Sephadex-G25 were obtained from Amersham Biosciences (Uppsala, Sweden); peroxidase-conjugated goat anti-rabbit IgG was purchased from BoaoBioTech (Beijing, People’s Republic of China); human fibrinogen, FPA, FPB, phenylmethanesulfonyl fluoride (PMSF), egg-yolk L-α-phosphatidylcholine, and bovine brain L-α-phosphatidylserine were from Sigma-Aldrich Co. (St Louis, MO, USA); human prothrombin (FII), thrombin, active factor V (FVa), FVII/VIIa, factor IX (FIX)/IXa, and FX/Xa were purchased from Hematologic Technologies (Burlington, VT, USA); the chromogenic substrate H-D-Phe-Pip-Arg-pNa•2HCl (S2238) was from Hyphen BioMed (Neuville-Sur-Oise, France); rabbit anti-HCA polyclonal antibodies were prepared in our laboratory as described in Supplementary materials (section “The preparation of polyclonal antibody”) and its ELISA titer was above 1:1,000,00.
Techniques: High Content Screening, Activity Assay, Coagulation